Navigation Links
Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
Date:9/10/2008

BEIJING, Sept. 10 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced the market launch of Anflu(R), a seasonal influenza vaccine, for 2008-2009 Flu Season. Developed and manufactured by Sinovac, Anflu(R) is the only split influenza vaccine produced without preservatives in China. Sinovac is undertaking the sales and marketing program utilizing its established sales force to promote the adult dosage form of Anflu(R).

Utilizing the virus strain for the Northern Hemisphere recommended by the World Health Organization, Sinovac has commenced the production of Anflu(R) for the annual flu season based on its 2008-2009 production plan. The Chinese authorities have recently completed the review of the batch release process and approved the vaccine for launch. In August 2008, the China CDC issued the 2008 "Guidelines for Influenza Prevention and Control Technology" that highlighted the positive public health implications of receiving the seasonal flu vaccine, the target population and the extension of the vaccination duration. As an amendment to the 2007 version, the 2008 guidance expanded the recommended vaccination population to include people living in senior homes, nursing homes and chronic disease nursing facilities, along with childcare providers who are looking after infants less than six month in age.

Over the past year, Sinovac has expanded its manufacturing capacity with the construction of a pandemic influenza vaccine production line with annual capacity of 20 million doses using the grant from China's National Development and Reform Commission. The production line includes state-of-the-art automated production equipment along with an expanded packaging capability and affords Sinovac the ability to produce up to five million doses of Anflu(R). By leveraging the latest production technology, the quality of the Anflu vaccine will be enhanced.

In line with its efforts incorporat
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sinovac Adjourns Annual General Meeting
2. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
3. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
4. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
5. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
6. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
7. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
8. Sinovac Biotech Holds Annual General Meeting
9. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
10. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
11. Sinovac Announces Adjournment of Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... be used for detailed studies of what happens on ... pharmaceuticals research, among other applications. A group of researchers ... artificial cell membranes form across a large number of ... between the interior of a cell and its surroundings ... a surface layer that holds the cell together and ...
(Date:9/2/2014)... 2014 Persistence Market Research ( ... Pharmaceutical, Biopharma and Life Sciences: North America ... membrane technology market for pharmaceutical, biopharma and life sciences is ... expected to grow at a CAGR of 9.1% from ... USD 10,886.0 million in 2019. Browse the ...
(Date:9/2/2014)... Myriant Corporation, a global renewable chemicals ... agreement with Azelis Group, a specialty chemicals distribution ... in the Nordics, Benelux, France, Iberia, Italy, the ... industrial and base chemicals markets. , “As a ... chemical portfolio with extensive distribution networks providing Myriant ...
(Date:9/2/2014)... Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... announced the appointment of Debra Zack , ... appointment of Lloyd Rowland , senior vice ... "Debra,s expertise in biologics clinical development ...
Breaking Biology Technology:Nano-forests to reveal secrets of cells 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3
... release is available in German . ... with microelectronic components gradually being replaced by nanoelectronic ... the present stage the most commonly used material ... further miniaturization and technological progress. New electronic materials ...
... Rosei of the INRS Energy Materials Telecommunications Center has ... Friedrich Wilhelm Bessel Research Award given by the Alexander ... awards annually to young, high level researchers around the ... caliber and scope of his research in the field ...
... PharmAthene, Inc. (NYSE Amex: PIP ), a ... threats, today reported financial and operational results for the ... For the third quarter of 2010, PharmAthene ... in the same period of 2009.  For the nine ...
Cached Biology Technology:Step by step toward tomorrow's nanomaterial 2INRS professor Federico Rosei receives a 2010 Friedrich Wilhelm Bessel Research Award 2PharmAthene Reports Third Quarter 2010 Financial and Operational Results 2PharmAthene Reports Third Quarter 2010 Financial and Operational Results 3PharmAthene Reports Third Quarter 2010 Financial and Operational Results 4PharmAthene Reports Third Quarter 2010 Financial and Operational Results 5PharmAthene Reports Third Quarter 2010 Financial and Operational Results 6PharmAthene Reports Third Quarter 2010 Financial and Operational Results 7
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... issue of The FASEB Journal , ... the leading cause of blindness in adults, diabetic ... advance involves quantifying the early molecular changes caused ... Using new probes developed by scientists, they were ... diabetic retinopathy. , "My goal is to establish ...
(Date:9/2/2014)... 2, 2014 Best-selling author Sam Kean stops by ... Megalodon, the 50-foot super shark that, despite what "Shark ... Learn all about it at http://youtu.be/KhFygIoW_MA . , ... of Madness, Love and the History of the World ... the Reactions treatment in a 10-episode video series produced ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... The apparently random self-assembly of molecular threads into the ... frantic than previously thought, Michigan State University scientists say. ... the nature of some diseases. How proteins spontaneously ... wide variety of functional or malfunctioning three-dimensional ...
... A phylogenetic analysis can take a long time to ... efficiently and effectively. The National Institute for Mathematical and ... focusing on high performance computing (HPC) for phylogenetics. ... to use TeraGrid, the CIPRES Portal, the iPlant Discovery ...
... The American Physical Society (APS) announces a new public ... public libraries in the United States full use of ... back to the first issue in 1893, a collection ... provide this access at no cost to participating public ...
Cached Biology News:Scientists post lower speed limit for cell-signaling protein assembly 2
Anti-Human Factor XI Purified (Polyclonal) (sheep IgG)...
...
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Biology Products: